Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Lymphoid 1CNS 1

Conditions

Neoplasms 7Carcinoma, Hepatocellular 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Prostatic Neoplasms 4Breast Neoplasms 4Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Head and Neck Neoplasms 3Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Neuroblastoma 1Nephrotic Syndrome 1Neoplasms, Plasma Cell 1NSCLC 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Recurrence × Pharmaceutical Preparations × Clear all
NCT06208657 2026-01-28

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Australian & New Zealand Children's Haematology/Oncology Group

Phase 1/2 Recruiting
90 enrolled
CNSLymphoid

Lymphoma, Neoplasms, Recurrence, Central Nervous System Neoplasms

NCT07347977 2026-01-16

LidCRM

First Affiliated Hospital of Ningbo University

Phase NA Not yet recruiting
1,400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT01544322 2015-06-18

ME-344-001

MEI Pharma, Inc.

Phase 1 Completed
24 enrolled

Neoplasm Metastasis, Recurrence

NCT01401868 2013-06-24

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

MEI Pharma, Inc.

Phase 1 Completed
18 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡